Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.

Trial Profile

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2015

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms Maximiza
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 May 2012 Planned end date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 08 Sep 2010 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top